Orgenesis Inc. Income Tax Provision

Income Tax Provision of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Income Tax Provision growth rates and interactive chart. The actual income tax expense for the applicable year.


Highlights and Quick Summary

  • Income Tax Provision for the quarter ending September 29, 2021 was $67 Thousand (a -3450.0% decrease compared to previous quarter)
  • Year-over-year quarterly Income Tax Provision decreased by -472.22%
  • Annual Income Tax Provision for 2020 was $-1.61 Million (a 602.62% increase from previous year)
  • Annual Income Tax Provision for 2019 was $-229 Thousand (a -117.13% decrease from previous year)
  • Annual Income Tax Provision for 2018 was $1.34 Million (a 0.0% decrease from previous year)
  • Twelve month Income Tax Provision ending September 29, 2021 was $-1.51 Million (a -3.52% decrease compared to previous quarter)
  • Twelve month trailing Income Tax Provision increased by 787.65% year-over-year
Trailing Income Tax Provision for the last four month:
29 Sep '21 30 Mar '21 30 Dec '20 29 Sep '20
$-1.51 Million $-1.56 Million $-1.61 Million $-170 Thousand
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Income Tax Provision of Orgenesis Inc.

Most recent Income Tax Provisionof ORGS including historical data for past 10 years.

Interactive Chart of Income Tax Provision of Orgenesis Inc.

Orgenesis Inc. Income Tax Provision for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.07 $-0.0
2020 $-1.56 $-0.02 $0.01 $-0.05 $-1.61
2019 $-0.12 $-0.04 $-0.02 $-0.05 $-0.23
2018 $-0.43 $2.35 $-0.28 $-0.4 $1.34
2017 $0.42 $-0.44 $0.52 $-1.31
2016 $0.52 $-0.37 $-0.63 $-0.63 $-1.55
2015 $-0.9
2012 $0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.